A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf(Fred Hutch Cancer Center), Frederick R. Appelbaum(City Of Hope National Medical Center), Patrick J. Stiff(Loyola University Medical Center), Roland B. Walter(University of Washington), Robert K. Stuart(Memorial Sloan Kettering Cancer Center), Joseph Brandwein(Goethe University Frankfurt), Thomas J. Nevill(Vancouver General Hospital), Martin S. Tallman(Midwestern University), Cheryl L. Willman(University of New Mexico), Richard A. Larson(Wayne State University), Marilyn L. Slovak(City Of Hope National Medical Center), Kenneth J. Kopecky(City Of Hope National Medical Center), Harry P. Erba(Michigan Center for Translational Pathology), Leif Stenke(Karolinska Institutet)
Cited by 632
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k